International Journal of Hematology

Papers
(The H4-Index of International Journal of Hematology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID-19-associated coagulopathy and disseminated intravascular coagulation289
Recent advances in the research and management of sepsis-associated DIC55
Engineering the next generation of CAR-NK immunotherapies51
Multiple myeloma with high-risk cytogenetics and its treatment approach44
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine37
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia35
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment32
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm24
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination23
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia22
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR us19
Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma19
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study19
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives18
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities17
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients17
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation17
0.037956953048706